ITIF Logo
ITIF Search

Keysha Brooks-Coley

Keysha Brooks-Coley

Senior Director, Advocacy Strategic Alliances

Cancer Action Network, American Cancer Society

Keysha Brooks-Coley is a Senior Director, Advocacy Strategic Alliances, with the American Cancer Society Cancer Action Network (ACS CAN). Keysha’s portfolio of federal health policy issues includes private health insurance, Medicare, FDA drug development issues, and health care quality issues including palliative care, and pain management. Keysha also serves as Executive Director of the ACS CAN lead Patient Quality of Life Coalition. The coalition was established by ACS CAN in 2013 to advance the interests of patients and families facing serious illness and has a membership of over 40 patient, provider, and health system organizations. In addition to her policy portfolio Keysha also leads efforts at ACS CAN to foster greater alliances with patient and provider groups on priority policy issues.

Keysha previously served as Professional Staff Member on the United States Senate Committee on Health, Education, Labor, and Pensions, Subcommittee on Retirement Security and Aging, Majority staff for Senator Barbara Mikulski (MD) from 2003-2008. Her policy responsibilities included a wide range of aging and health policy issues including women’s health, public health, biomedical research, health disparities and Health and Human Services Appropriations.

Before joining the Subcommittee staff, Keysha served on the staff of Congresswoman Marcy Kaptur (OH) in the United States House of Representatives from 2000-2003 as a Legislative Assistant for health care, aging, and education issues.

Keysha has a BA degree in Sociology and Political Science from Towson University and a Master’s degree in Political Management from the George Washington University.

Recent Events and Presentations

June 6, 2017

Speeding Cures for Patients: How Congress Can Update the Prescription Drug User Fee Act to Spur Biopharmaceutical Innovation

For more than two decades, the Prescription Drug User Fee Act (PDUFA) has underpinned America’s leadership in biopharmaceutical innovation. Join ITIF for a discussion with policy experts, industry leaders, and patient advocates to discuss why a timely reauthorization of PDUFA is critical to the future of medical innovation.

Back to Top